In preclinical studies, short-term treatment with 5-HT4R agonists, including RS67333, has anxiolytic and antidepressant properties and mimics the cellular and molecular AD responses achieved after chronic SSRI administration [15–19]. Here, HTR4 is linked to Alzheimer disease.